Search research articles
Contact Us
Filters
Showing results (101-110 of 105) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 105 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
J-C Soria, A Fülöp, C Maciel, et al.
International Journal of Cancer
|
September 27, 2018
Identification of a highly lethal V3<sup>+</sup> TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma
P Christopoulos, M Kirchner, F Bozorgmehr, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 17, 2002
Report from the first meeting of the 'European Network on Translational Research in Lung Cancer Amsterdam-Barcelona-Bialystok-Heidelberg'. Thoraxklinik Heidelberg, Germany, July 25, 2001
J R Fischer, P Baas, H D Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
M Joerger, J von Pawel, S Kraff, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 2, 2020
Risk stratification of EGFR<sup>+</sup> lung cancer diagnosed with panel-based next-generation sequencing
P Christopoulos, M Kirchner, J Roeper, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 105) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 105 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
J-C Soria, A Fülöp, C Maciel, et al.
International Journal of Cancer
|
September 27, 2018
Identification of a highly lethal V3<sup>+</sup> TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma
P Christopoulos, M Kirchner, F Bozorgmehr, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 17, 2002
Report from the first meeting of the 'European Network on Translational Research in Lung Cancer Amsterdam-Barcelona-Bialystok-Heidelberg'. Thoraxklinik Heidelberg, Germany, July 25, 2001
J R Fischer, P Baas, H D Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
M Joerger, J von Pawel, S Kraff, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 2, 2020
Risk stratification of EGFR<sup>+</sup> lung cancer diagnosed with panel-based next-generation sequencing
P Christopoulos, M Kirchner, J Roeper, et al.
Page
of 11